ICL-CCIC-0019 is a choline kinase alpha (CHKA) inhibitor. ICL-CCIC-0019 decreases phosphocholine levels and the fraction of labeled choline in lipids, and induces G1 arrest, endoplasmic reticulum stress and apoptosis of a panel of 60 cancer cell lines. References: Trousil S, Kaliszczak M, Schug Z, Nguyen QD, Tomasi G, Favicchio R, Brickute D, Fortt R, Twyman FJ, Carroll L, Kalusa A, Navaratnam N, Adejumo T, Carling D, Gottlieb E, Aboagye EO. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget. 2016 Jun 14;7(24):37103-37120. doi: 10.18632/oncotarget.9466. PubMed PMID: 27206796; PubMed Central PMCID: PMC5095062.

纯度：≥98%

CAS：936498-64-5